+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route of Administration, Patient Type, End User - Global Forecast to 2030- Product Image
Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route of Administration, Patient Type, End User - Global Forecast to 2030- Product Image
Sale

Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route of Administration, Patient Type, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716081
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetes Associated Ophthalmic Treatment Market grew from USD 6.18 billion in 2024 to USD 6.74 billion in 2025. It is expected to continue growing at a CAGR of 8.67%, reaching USD 10.19 billion by 2030.

Setting the Stage for Ophthalmic Care in Diabetes

The landscape of ophthalmic care for individuals living with diabetes has undergone profound evolution, driven by rising disease prevalence and breakthroughs in therapeutic science. As diabetes continues to affect millions globally, vision-threatening complications such as diabetic retinopathy and diabetic macular edema have moved to the forefront of clinical concern. Cutting-edge pharmacological innovations now offer targeted inhibition of pathological angiogenesis, while advances in sustained-release technologies and surgical techniques expand the horizon of clinical options.

This executive summary distills the critical forces shaping the market, from shifting regulatory frameworks to emerging patient care models. It highlights the transformative potential of personalized medicine approaches, underscores the interplay between economic factors and treatment accessibility, and reveals how the convergence of digital diagnostics and teleophthalmology is redefining early intervention paradigms. By synthesizing these key dimensions, this introduction establishes a foundation for strategic decision-making, guiding stakeholders toward opportunities for collaboration, investment, and therapeutic advancement in the field of diabetes-associated ophthalmic treatment.

Emerging Dynamics Redefining Ophthalmic Diabetes Therapies

The last decade has witnessed remarkable shifts that are redefining the standard of care for diabetic eye disease. First, the transition from monotherapy injections to multi-pathway targeting agents has broadened the therapeutic spectrum, enabling clinicians to tailor regimens to individual patient profiles. In parallel, the integration of real-world evidence into clinical guidelines is accelerating drug adoption cycles, as payers and providers demand data demonstrating both efficacy and cost-effectiveness.

Simultaneously, the integration of artificial intelligence into retinal imaging platforms is enhancing diagnostic precision and enabling earlier identification of microvascular changes. This digital transformation is complemented by the emergence of sustained-release implants and depot formulations designed to reduce treatment burden and improve patient adherence. These concurrent shifts are forging a new era of proactive management, where predictive analytics guide treatment initiation and optimization, ensuring that therapeutic interventions align with evolving clinical trajectories.

Assessing the Fallout from US Tariffs on Ophthalmic Treatment Supply Lines

The introduction of new tariffs on pharmaceutical imports and medical devices in the United States in 2025 has introduced a complex layer of economic pressure. Manufacturers reliant on international supply chains for active pharmaceutical ingredients and specialized delivery systems are grappling with increased input costs. This development has prompted a reevaluation of production footprints, with some companies relocating manufacturing closer to domestic facilities to mitigate tariff exposure.

Concurrently, the ripple effect of these tariffs is influencing pricing negotiations with payers and hospital systems. In response, many industry participants are adopting value-based contracting models, aligning reimbursement with demonstrable patient outcomes to justify premium pricing. Moreover, these trade measures have accelerated efforts to diversify sourcing channels and strengthen relationships with regional suppliers, ultimately reshaping the global distribution of diabetes-associated ophthalmic treatments.

Unpacking Treatment, Administration, Patient, and End User Patterns

A nuanced understanding of market segmentation reveals critical pathways for targeted growth. Within the realm of treatment type, anti-VEGF therapies dominate therapeutic protocols with agents such as aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab leading injection-based approaches. Corticosteroid options-embodied by dexamethasone implants, fluocinolone implants, and triamcinolone-address persistent inflammation in complex cases, while laser therapies encompassing both focal/grid photocoagulation and panretinal photocoagulation remain indispensable in advanced proliferative disease. Surgical interventions serve as a vital recourse when pharmacologic and laser modalities prove insufficient, underscoring the multifaceted nature of clinical decision-making.

Examining the route of administration offers further insight: intravitreal injections delivered via prefilled syringes or vials ensure precise dosing directly to the vitreous cavity, while systemic options-both intravenous and oral-provide adjunctive control in cases with systemic comorbidities. Topical formulations, including eye drops and ointments, facilitate patient-administered management of anterior segment inflammation and superficial ocular complications. This layered perspective on delivery mechanisms underscores the importance of matching therapeutic form with disease phenotype and patient preference.

Patient type segmentation, distinguishing between type 1 and type 2 diabetes, highlights divergent disease trajectories and response patterns, informing both clinical trial design and real-world evidence generation. End user channels span ambulatory surgical centers, hospitals, ophthalmology clinics, and retail pharmacies, each presenting unique operational considerations and reimbursement frameworks. Together, these segmentation dimensions offer a roadmap for stakeholder engagement, product positioning, and investment prioritization.

Regional Nuances Shaping Market Potential

Geographic variations in healthcare infrastructure, regulatory environments, and economic landscapes profoundly shape the uptake of ophthalmic therapies. In the Americas, mature markets leverage established reimbursement mechanisms and innovative care delivery models, driving rapid adoption of next-generation anti-VEGF agents and sustained-release implants. Patients and providers benefit from integrated electronic health record systems and coordinated care pathways that streamline diagnosis and follow-up.

Within Europe, the Middle East, and Africa, regulatory harmonization efforts are converging to accelerate market entry, yet disparities in healthcare access persist across regions. While Western European nations boast robust clinical trial networks and favorable pricing benchmarks, emerging economies in the Middle East and Africa increasingly explore public-private partnerships to expand retinal care services and invest in diagnostic infrastructure.

The Asia-Pacific region presents a dual narrative of opportunity and challenge. Large patient populations, rising diabetes incidence, and expanding healthcare budgets create fertile conditions for innovative treatments. At the same time, variations in reimbursement policies and physician training levels require adaptive market access strategies. Collaborative efforts to build center-of-excellence networks and digital screening programs are proving instrumental in addressing unmet needs and scaling sustainable models of care.

Competitive Narratives Driving Innovation and Collaboration

The competitive landscape is characterized by a blend of established pharmaceutical powerhouses and agile biotech innovators, each vying to define the next standard of care. Leading the charge in anti-VEGF innovation, companies with commercially successful agents are investing heavily in life-cycle management through novel formulations and extended dosing intervals. Meanwhile, emerging biotech firms are harnessing advances in molecular engineering to develop bispecific antibodies and cell-based therapies aimed at comprehensive retinal protection.

Strategic alliances between pharmaceutical and device manufacturers are intensifying, reflecting a shared ambition to integrate delivery platforms with pharmacology. Collaborative research agreements enable rapid iteration of depot technologies and smart implants equipped with sensor feedback mechanisms. Concurrently, contract research organizations and academic partnerships play pivotal roles in accelerating early-phase clinical development, providing specialized expertise and access to diverse patient cohorts.

This dynamic environment fosters a continuum of innovation while compelling incumbents to refine value propositions. As market leaders navigate patent expirations and biosimilar entry, they are pivoting toward combination therapies and personalized treatment algorithms, thereby sustaining differentiation and reinforcing long-term growth trajectories.

Strategic Imperatives for Decision-Makers in Ophthalmology

Industry leaders should prioritize investment in next-generation platforms that offer extended durability and predictable dosing profiles, reducing the clinical burden associated with frequent interventions. By allocating resources to research on predictive biomarkers and precision medicine, stakeholders can better stratify patient populations and optimize therapeutic outcomes. Diversifying manufacturing bases and forging strategic partnerships with regional suppliers will buffer against global trade disruptions and ensure continuity of supply.

Adopting digital health solutions-from AI-based screening tools to remote monitoring applications-can enhance patient engagement and enable earlier intervention, ultimately reducing the incidence of advanced retinopathy. Developing flexible pricing models tied to real-world performance will facilitate market access and align stakeholder incentives. Finally, building multidisciplinary coalitions that unite payers, providers, patient advocacy groups, and policymakers can drive holistic improvements in care delivery and reimbursement frameworks across diverse geographies.

Rigorous Methodology Ensuring Analytical Integrity

This report synthesizes insights from a rigorous dual-track research approach. Secondary research draws upon peer-reviewed journals, regulatory agency publications, corporate filings, and industry white papers to map current and emerging trends. Primary research encompasses structured interviews with key opinion leaders, including retina specialists, healthcare economists, and payers, as well as advisory boards convened to validate assumptions and interpret nuanced market signals.

Quantitative modeling applies granular segmentation parameters-spanning treatment modalities, administration routes, patient types, and end user channels-to ensure robust cross-validation. Data triangulation techniques reconcile disparate sources, while sensitivity analyses test the resilience of conclusions under varying market scenarios. This comprehensive methodology underpins the report’s strategic frameworks, equipping stakeholders with actionable intelligence grounded in empirical evidence and expert insight.

Harnessing Insights to Navigate Future Ophthalmic Diabetes Therapies

The convergence of scientific innovation, evolving regulatory landscapes, and shifting economic forces presents both challenges and opportunities in the field of diabetes-associated ophthalmic treatments. By leveraging the insights outlined in this summary, stakeholders can navigate complex trade dynamics, tailor strategies to granular market segments, and capitalize on regional growth pockets. The future trajectory of care hinges on collaborative models that integrate cutting-edge therapeutics with digital diagnostics and value-based pricing.

As the market continues to evolve, proactive engagement with emerging technologies and flexible partnership structures will define leaders in this domain. The actionable recommendations provided herein serve as a blueprint for prioritizing investments, refining operational models, and forging alliances that accelerate patient access to life-changing therapies. Embracing this strategic vision will ensure that advances in ophthalmic care translate into real-world improvements for individuals living with diabetes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Anti-VEGF
      • Aflibercept
      • Bevacizumab
      • Brolucizumab
      • Faricimab
      • Ranibizumab
    • Corticosteroids
      • Dexamethasone Implant
      • Fluocinolone Implant
      • Triamcinolone
    • Laser Therapy
      • Focal/Grid Photocoagulation
      • Panretinal Photocoagulation
    • Surgical Intervention
  • Route Of Administration
    • Intravitreal Injection
      • Prefilled Syringe
      • Vial
    • Systemic
      • Intravenous
      • Oral
    • Topical
      • Eye Drops
      • Ointments
  • Patient Type
    • Type 1 Diabetes
    • Type 2 Diabetes
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Ophthalmology Clinics
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • AbbVie Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Sandoz International GmbH
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd
  • Intas Pharmaceuticals Ltd

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetes Associated Ophthalmic Treatment Market, by Treatment Type
8.1. Introduction
8.2. Anti-VEGF
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Brolucizumab
8.2.4. Faricimab
8.2.5. Ranibizumab
8.3. Corticosteroids
8.3.1. Dexamethasone Implant
8.3.2. Fluocinolone Implant
8.3.3. Triamcinolone
8.4. Laser Therapy
8.4.1. Focal/Grid Photocoagulation
8.4.2. Panretinal Photocoagulation
8.5. Surgical Intervention
9. Diabetes Associated Ophthalmic Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intravitreal Injection
9.2.1. Prefilled Syringe
9.2.2. Vial
9.3. Systemic
9.3.1. Intravenous
9.3.2. Oral
9.4. Topical
9.4.1. Eye Drops
9.4.2. Ointments
10. Diabetes Associated Ophthalmic Treatment Market, by Patient Type
10.1. Introduction
10.2. Type 1 Diabetes
10.3. Type 2 Diabetes
11. Diabetes Associated Ophthalmic Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Ophthalmology Clinics
11.5. Retail Pharmacies
12. Americas Diabetes Associated Ophthalmic Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Diabetes Associated Ophthalmic Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Diabetes Associated Ophthalmic Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd
15.3.2. Regeneron Pharmaceuticals, Inc.
15.3.3. Bayer AG
15.3.4. Novartis AG
15.3.5. AbbVie Inc.
15.3.6. Alcon Inc.
15.3.7. Bausch Health Companies Inc.
15.3.8. Sandoz International GmbH
15.3.9. Chengdu Kanghong Pharmaceutical Group Co., Ltd
15.3.10. Intas Pharmaceuticals Ltd
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 69. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 70. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 73. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 74. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 75. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 79. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 84. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 130. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 132. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 135. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 136. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 140. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 142. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 145. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 146. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 160. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 161. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 162. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 164. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 165. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 166. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 170. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 175. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 176. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 210. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 215. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 216. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 230. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 231. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 232. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 234. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 235. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 236. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 240. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 245. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 246. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 270. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 275. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 276. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 280. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Diabetes Associated Ophthalmic Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • AbbVie Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Sandoz International GmbH
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd
  • Intas Pharmaceuticals Ltd

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.74 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.19 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Diabetes Associated Ophthalmic Treatment - Global Strategic Business Report - Product Image

Diabetes Associated Ophthalmic Treatment - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Application, By Type (Drugs, Devices), By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Application, By Type (Drugs, Devices), By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030 - Product Image

Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030

  • Report
  • 110 Pages
  • Global
From
Smart Insulin Pens & Pumps Market by Product Type, Treatment Type, Distribution Channel, Diabetes Type, End User - Global Forecast to 2030 - Product Image

Smart Insulin Pens & Pumps Market by Product Type, Treatment Type, Distribution Channel, Diabetes Type, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Needle Free Diabetes Care Market by Application, Product Type, Age Group, End User, Distribution Channel, Technology - Global Forecast to 2030 - Product Image

Needle Free Diabetes Care Market by Application, Product Type, Age Group, End User, Distribution Channel, Technology - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From

About the Diabetes Associated Ophthalmic Treatment Market

The Diabetes Associated Ophthalmic Treatment market encompasses a range of medical procedures, devices, and medications utilized in the management and care of eye conditions associated with diabetes, specifically diabetic retinopathy and diabetic macular edema. Diabetic retinopathy involves changes to retinal blood vessels that can cause them to bleed or leak fluid, distorting vision. Treatments for these conditions range from laser surgery to control bleeding to the administration of anti-VEGF drugs, which help to reduce abnormal blood vessel growth and swelling. Intravitreal injections of steroids can also be utilized for their anti-inflammatory effects. Additionally, there is a growing interest in the development and use of novel drug delivery systems and surgical instruments to improve the precision and efficacy of treatments. Furthermore, technological advancements in optical coherence tomography (OCT) aids in the early detection and management of diabetic eye diseases by providing high-resolution images of the retina. Regular screening among diabetic patients is crucial for early intervention and has become an integral part of diabetes care, helping to prevent vision loss. Several companies have established positions in the market, which include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Abbott. These companies are involved in the production of therapeutics like anti-VEGF injections, as well as manufacturing devices and supplies for laser treatments and surgeries tailored to mitigate the ocular complications that arise from diabetes. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.